Literature DB >> 6477362

Comparison of tumor response in nude mice and in the patients.

H H Fiebig, C Schuchhardt, H Henss, L Fiedler, G W Löhr.   

Abstract

In 34 tumors of different origin 50 comparisons between the tumor response in the patients and in nude mice were performed. Combination chemotherapy was more successful than single agent chemotherapy. Out of the 25 combinations given, 9 (36%) effected a remission in comparison to 4 out of 25 (16%) after single agent chemotherapy. 13 patients got a remission which was found in 12 cases in the nude mouse, too. 37 patients did not respond to treatment and the same result was found in 36 cases in the nude mouse system. Xenografts gave a correct prediction for resistance in 97% and for tumor response in 92%. Despite great efforts to obtain a large number of comparisons, only 22 test results were available before the patients needed chemotherapy. In 13 cases chemotherapy was done simultaneously in the patient and in the nude mouse system. In 15 cases the patients were treated first. The xenograft system will not have practical significance in determining the treatment of the patients. Limitations are the duration of the testing, the testing rate of about 50% and the charges for nude mice. However, the highly correct prediction rates for tumor sensitivity and resistance validates human tumor xenografts as tumor models to test new drugs and combinations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6477362

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  21 in total

Review 1.  Preclinical mouse cancer models: a maze of opportunities and challenges.

Authors:  Chi-Ping Day; Glenn Merlino; Terry Van Dyke
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

2.  CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts.

Authors:  H H Fiebig; K H Widmer; B R Winterhalter; G W Löhr
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

4.  Influence of dispase and angiogenesis factors on the growth of human xenografts.

Authors:  P Köpf-Maier; U Kestenbach
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.

Authors:  P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  Development of new anti-cancer drugs.

Authors:  H M Pinedo
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

7.  Antitumor activity of treosulfan against human breast carcinomas.

Authors:  P Köpf-Maier; G Sass
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract.

Authors:  P Köpf-Maier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Organoid reorganization of human tumors under in vitro conditions.

Authors:  P Köpf-Maier; B Zimmermann
Journal:  Cell Tissue Res       Date:  1991-06       Impact factor: 5.249

10.  In vitro and in vivo cytotoxicity of alkyl lysophospholipid ET-18-OCH3 and thioether lipid BM 41.440.

Authors:  G H Leder; H H Fiebig; E Wallbrecher; B R Winterhalter; G W Löhr
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.